Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Non-randomized, Open-label, Non-controlled, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics/ Pharmacodynamics of BAYQ3939 (400 mg BID and 400 mg TID) in Hospitalized Patients With Severe Bacterial Pneumonia or Bacterial Pneumonia With a Poor Response to Other Antimicrobials.

Next Previous
X
Search
Trial Profile

A Prospective, Non-randomized, Open-label, Non-controlled, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics/ Pharmacodynamics of BAYQ3939 (400 mg BID and 400 mg TID) in Hospitalized Patients With Severe Bacterial Pneumonia or Bacterial Pneumonia With a Poor Response to Other Antimicrobials.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciprofloxacin (Primary)
  • Indications Bacterial infections; Community-acquired pneumonia; Nosocomial pneumonia
  • Focus Adverse reactions; Pharmacokinetics; Registrational
  • Sponsors Bayer

    • Most Recent Events

    • 26 Apr 2015 Status changed from recruiting to completed as reported by ClimicalTrials.gov record.
    • 16 Sep 2014 Planned number of patients changed from 30 to 46, as reported by ClinicalTrials.gov.
    • 14 Apr 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2014 to 1 Apr 2015.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top